Revolutionizing Cancer Diagnostics Through AI-Powered Analysis With Waqas Haque, MD, and Aamir Ehsan, MD

In this episode of Exploring Artificial Intelligence in Oncology, Dr. Waqas Haque, MD, sits down with Aamir Ehsan, MD, the Founder and CEO of CorePath Laboratories in San Antonio, Texas. Together they discuss how CorePath utilizes AI in pathology, including the following topics:

• Improvements in diagnostic accuracy and efficiency through CorePath’s AI diagnostics
• CorePath’s collaboration with the Genomic Testing Cooperative in using AI for next-generation sequencing (NGS) diagnostics
• Reasons as to why all hospitals in America don’t utilize AI-powered pathology tools in their clinical workflows
• How CorePath balances the use of AI and human expertise in diagnostics
• Ongoing research and development projects at CorePath aimed at further enhancing AI capabilities in pathology
• And more!

This episode is also available as a podcast. Click here to listen!

About Dr. Haque and Dr. Ehsan

Waqas Haque, MD, MPH, is a Hematology/Oncology Fellow at the University of Chicago. He recently completed his Internal Medicine Residency at New York University (NYU) in a Clinical Investigator Track. Dr. Haque has balanced his patient care work with a variety of research projects. During his fellowship training at the University of Chicago, he plans to further his work in innovative clinical trial design, value-based care delivery to cancer patients, and clinical investigation.

Aamir Ehsan, MD, is the Founder and CEO of CorePath Laboratories in San Antonio, Texas. He specializes in anatomic and clinical pathology, hematopathology, molecular genetics, and transfusion medicine. Over the years, Dr. Ehsan has continually contributed to research and science through peer-reviewed articles, textbook chapters, and presentations at national and international conferences.